富美實 (FMC) 2026 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Ladies and gentlemen, thank you for joining us. Welcome to the second-quarter 2026 earnings call for FMC Corporation. This event is being recorded. (Operator Instructions)

    各位女士、先生,感謝各位加入我們。歡迎參加 FMC Corporation 2026 年第二季財報電話會議。本活動將被錄音。(接線員指示)

  • I will now hand the conference over to Mr. Curt Brooks, Director of Investor Relations for FMC Corporation. Please go ahead.

    我現在把會議交給 FMC Corporation 投資人關係總監 Curt Brooks 先生。請開始。

  • Curt Brooks - Director of Investor Relations

    Curt Brooks - Director of Investor Relations

  • Good morning. Welcome to FMC Corporation's 2026 second-quarter earnings call.

    各位早安。歡迎參加 FMC Corporation 2026 年第二季財報電話會議。

  • Today's prepared remarks will be provided by Pierre Brondeau, Chairman, Chief Executive Officer and President; and Andrew Sandifer, Executive Vice President and Chief Financial Officer. After prepared comments, we will take questions. Our earnings release and today's slide presentation are available on the FMC Investor Relations website, and the prepared remarks from today's discussion will be made available after the call.

    今天的預先準備發言將由董事長、執行長兼總裁 Pierre Brondeau,以及執行副總裁兼財務長 Andrew Sandifer 提供。在預先準備的評論之後,我們將進行問答。我們的財報新聞稿與今天的簡報投影片可於 FMC 投資人關係網站取得,而今天討論的預先準備發言稿也將在電話會議結束後提供。

  • Let me remind you that today's presentation and discussion will include forward-looking statements that are subject to various risks and uncertainties concerning specific factors, including but not limited to those factors identified in our earnings release and in our filings with the Securities and Exchange Commission. Information presented represents our best judgment based on today's understanding. Actual results may vary based on these risks and uncertainties.

    提醒各位,今天的簡報與討論將包含前瞻性陳述,並受多項風險與不確定性影響,涉及特定因素,包括但不限於我們財報新聞稿及向美國證券交易委員會提交之文件中所辨識的因素。所呈現之資訊係基於我們對今日情況的理解所作出的最佳判斷。實際結果可能因上述風險與不確定性而有所差異。

  • Today's discussion and the supporting materials will include references to adjusted EPS, adjusted EBITDA, free cash flow, organic revenue growth, and revenue excluding India, all of which are non-GAAP financial measures. Please note that as used in today's discussion, earnings means adjusted earnings, EBITDA means adjusted EBITDA and sales refers to sales excluding India. A reconciliation and definition of these terms as well as other non-GAAP financial terms, to which we may refer during today's conference call, are provided on our website.

    今天的討論與相關資料將提及調整後每股盈餘(adjusted EPS)、調整後 EBITDA、自由現金流、有機營收成長,以及不含印度的營收,以上皆為非 GAAP 財務衡量指標。請注意,在今天的討論中,「earnings」指調整後盈餘,「EBITDA」指調整後 EBITDA,而「sales」指不含印度的銷售額。上述名詞及其他我們在今天電話會議中可能提及之非 GAAP 財務名詞的定義與調節表,已提供於我們的網站。

  • With that, I will now turn the call over to Pierre.

    接下來,我把電話會議交給 Pierre。

  • Pierre Brondeau - Chairman of the Board, Chief Executive Officer

    Pierre Brondeau - Chairman of the Board, Chief Executive Officer

  • Thank you, Curt. Good morning, everyone. In the second quarter, we continued to execute against our priorities. We delivered EBITDA above our guidance, generated meaningful free cash flow and advanced several initiatives that strengthen our balance sheet. Sales were below our expectation as a challenging operating environment, including geopolitical uncertainty, unfavorable weather and low insect pressure created additional pressure on both volume and price.

    謝謝你,Curt。各位早安。在第二季,我們持續依照既定優先事項執行。我們的 EBITDA 高於指引,產生了可觀的自由現金流,並推進多項強化資產負債表的措施。由於營運環境充滿挑戰,包括地緣政治不確定性、不利天候以及害蟲壓力偏低,對銷量與價格均造成額外壓力,銷售額低於我們的預期。

  • Growers and channel partners remain focused on managing costs and working capital, which resulted in cautious purchase pattern across many markets. Against this backdrop, we continued to make progress on our four operational pillars. Reducing debt, improving the competitiveness of our core portfolio, managing the post-patent transition for our next year, and growing new active ingredients. These pillars remain the foundation of the company's plan to improve earnings and cash generation while positioning FMC for future growth and the expanding contribution of its innovation pipeline.

    種植戶與通路夥伴仍聚焦於成本與營運資金管理,導致多數市場的採購模式趨於保守。在此背景下,我們在四大營運支柱上持續取得進展。包括降低負債、提升核心產品組合的競爭力、管理明年我們的專利到期後轉型,以及推動新活性成分成長。這些支柱仍是公司提升獲利與現金創造能力的計畫基礎,同時也讓 FMC 能夠把握未來成長與其創新研發管線擴大貢獻的機會。

  • With the equity investment from Tessenderlo Group marking the conclusion of the strategic review, we now have clarity on the path forward and are focused on execution. We made substantial progress during the quarter, particularly in strengthening our balance sheet through these reductions. Over the past several months, we announced the key components of our plan to generate $1 billion of proceeds to pay down debt.

    隨著 Tessenderlo Group 的股權投資標誌著策略檢討的結束,我們如今對未來路徑更為明確,並專注於執行。本季我們取得重大進展,尤其是透過這些降負債措施強化資產負債表。在過去幾個月中,我們公布了計畫的關鍵組成,目標是籌措 10 億美元資金用於償還債務。

  • These include signing a definitive agreement for the sale of our India commercial business for $252 million. Closing on the licensing agreement for rimisoxafen with Corteva and an upfront payment of $200 million. Entering into a framework agreement for a Newark, Delaware property for $114 million. Reaching an agreement with Tessenderlo Group for a $400 million minority equity investment. As well as progressing on several smaller asset sales. Together, these actions are expected to significantly strengthen our balance sheet and liquidity position.

    其中包括:簽署出售我們印度商業業務的最終協議,交易金額為 2.52 億美元。完成與 Corteva 就 rimisoxafen 的授權協議交割,並取得 2 億美元的預付款。就德拉瓦州紐瓦克(Newark, Delaware)一處不動產簽訂框架協議,金額為 1.14 億美元。與 Tessenderlo Group 達成 4 億美元少數股權投資協議。以及推進數項較小型資產出售。綜合而言,預期這些行動將顯著強化我們的資產負債表與流動性狀況。

  • Combined with a successful $1.2 billion secured bond offering we completed in May, they will provide greater financial flexibility as we continue to execute our strategy. Andrew will discuss the impact on our balance sheet and cash flow in more detail shortly. With debt reduction well underway, our attention remains on the operational actions that will improve business performance over time.

    再加上我們於 5 月完成的 12 億美元擔保債券成功發行,將在我們持續執行策略的同時,提供更大的財務彈性。Andrew 稍後將更詳細說明對資產負債表與現金流的影響。在降負債工作已順利展開之際,我們仍將重心放在能隨時間改善營運表現的各項營運行動上。

  • Turning to our second pillar, improving the competitiveness of our core portfolio. Over the past year, we have focused on simplifying how we operate, improving the efficiency of our manufacturing and supply chain network, and reducing structural costs across the business. These actions are intended to strengthen our competitive position and better align our cost structure with the markets we serve.

    接著談第二項支柱:提升核心產品組合的競爭力。過去一年,我們著重於簡化營運方式、提升製造與供應鏈網路效率,並降低全公司結構性成本。這些行動旨在強化我們的競爭地位,並使成本結構更貼近我們所服務的市場。

  • As previously announced, our objective is to exit active ingredients and formulation production assets that are no longer cost-competitive and transition production toward lower-cost sources. While this work remains underway, we are increasingly confident in the value it will deliver. In addition, we have made meaningful progress in realigning our supply chain and are beginning to see benefits from those efforts.

    如先前所宣布,我們的目標是退出已不具成本競爭力的活性成分與配方製造資產,並將生產轉向成本較低的來源。雖然此項工作仍在進行中,但我們對其可帶來的價值愈發有信心。此外,我們在供應鏈重新調整方面已取得實質進展,並開始看到這些努力帶來的效益。

  • Moving to our third pillar, we remain focused on executing a post-patent strategy for Rynaxypyr. We continue to see strong demand for our differentiated formulations and mixture. Sales of these products grew more than 35% year over year during the second quarter. We also remain focused on volume growth, outpacing lower pricing as the market evolves.

    第三項支柱方面,我們仍專注於執行 Rynaxypyr 的專利到期後策略。我們持續看到市場對我們具差異化的配方與混配產品有強勁需求。第二季這些產品的銷售額年增超過 35%。我們也持續聚焦於銷量成長,隨著市場演變,以銷量增長來超越較低的價格水準所帶來的影響。

  • Despite increased generic competition, branded diamide sales, excluding India, were essentially flat year over year. Over time, we expect branded diamide to grow in revenue as pricing stabilizes, and we continue to take market share from all the classes of insecticides. We are already seeing encouraging signs of volume growth.

    儘管學名藥競爭加劇,不含印度的品牌二醯胺(diamide)銷售額與去年同期基本持平。隨著價格趨於穩定,長期而言我們預期品牌二醯胺的營收將成長,且我們將持續自各類殺蟲劑中取得市占。我們已經看到令人鼓舞的銷量成長跡象。

  • In the second quarter, we saw very strong gains in hectares treated in key countries like Brazil, where product on the ground usage is up over 40%. These results reinforce our confidence in our post-patent strategy. Our fourth pillar remains on track with our expectations.

    第二季,我們在巴西等關鍵國家的施用面積(hectares treated)大幅成長,當地產品實際使用量增加超過 40%。這些結果進一步強化我們對專利到期後策略的信心。第四項支柱的進展也符合我們的預期。

  • During the quarter, we continued to advance registration and commercialization efforts around the world, including securing registration of Isoflex active in the EU, with launches expected to begin in 2027. As we have discussed previously, the pace of growth of new technology is influenced not only by customer adoption, but also by the timing of regulatory approvals and registrations, which are outside of our control. We continue to see external validation of the value of our innovation pipeline.

    本季,我們持續推進全球各地的登記與商業化工作,包括取得 Isoflex 活性成分在歐盟的登記,預計將自 2027 年開始上市。如我們先前所討論,新技術的成長速度不僅受客戶採用影響,也受監管核准與登記時程影響,而這些因素並非我們所能控制。我們持續看到外部對我們創新研發管線價值的肯定。

  • The licensing agreement for rimisoxafen with Corteva represents the third significant licensing agreement involving one of our proprietary active ingredients, following agreements of Isoflex active with Bayer and fluindapyr with Corteva.

    與 Corteva 就 rimisoxafen 達成的授權協議,是涉及我們自有活性成分的第三項重大授權協議,此前包括 Isoflex 活性成分與 Bayer 的協議,以及 fluindapyr 與 Corteva 的協議。

  • Turning to our second-quarter results on slide 4, 5, and 6, provide detail of our performance. The operating environment for crop chemicals remains challenging. Growers are faced with a difficult situation of low prices for many crops, combined with higher costs for inputs such as fertilizers and fuel, driven by the uncertain geopolitical environment.

    接著看投影片4、5與6上的第二季業績,將提供我們表現的細節。作物化學品的營運環境仍然充滿挑戰。種植戶面臨艱難處境:許多作物價格偏低,同時在不確定的地緣政治環境推動下,肥料與燃料等投入成本上升。

  • We are seeing growers respond to these margin pressures by carefully managing costs and reducing discretionary spending wherever possible. For crop protection chemicals, that can mean trading down to generic or reducing the number of applications. In addition, data from our proprietary Arc farm intelligence insect monitoring platform provides unique visibility into field conditions and indicates lower insect pressure so far this year.

    我們看到種植戶為因應這些利潤壓力,正透過審慎控管成本並在可行之處降低非必要支出。就作物保護化學品而言,這可能意味著改用學名藥或減少施用次數。此外,來自我們專有的 Arc 農場智慧昆蟲監測平台的數據,提供對田間狀況的獨特能見度,並顯示今年迄今昆蟲壓力較低。

  • With our current portfolio weighted more toward insecticide, this is especially relevant to FMC. We expect that over the next few years, the introduction and expansion of our new active ingredients will shift FMC to a more balanced portfolio with less reliance on insecticides and a stronger position in herbicides and fungicides. Our second-quarter revenue of $841 million, excluding India, was 1% lower than the low end of our guidance range.

    由於我們目前的產品組合較偏重殺蟲劑,這對 FMC 尤其重要。我們預期在未來幾年,隨著新有效成分的導入與擴張,FMC 的產品組合將轉向更均衡,降低對殺蟲劑的依賴,並在除草劑與殺菌劑方面建立更強的地位。我們第二季營收為 8.41 億美元(不含印度),較我們指引區間下緣低 1%。

  • As we forecasted, there were reduced orders from diamide partners, as well as expected registration losses in the EMEA. However, we encountered additional volume headwinds in North America as strained margins drove careful purchasing behavior for growers of non-specialty crops. Excessive heat in EMEA also led to lower than expected demand. We saw strong volume growth in new Rynaxypyr formulations, particularly in Brazil and North America.

    如我們先前預測,來自二醯胺合作夥伴的訂單減少,且 EMEA 也出現預期中的登記證流失。然而,我們在北美遭遇額外的銷量逆風,因利潤受壓使非專業作物的種植戶採取更審慎的採購行為。EMEA 的極端高溫也導致需求低於預期。我們看到新型 Rynaxypyr 配方的銷量強勁成長,尤其在巴西與北美。

  • New actives showed good growth, but we do not expect the bulk of the year-on-year increase to occur until the fourth quarter, when fluindapyr in LATAM and North America, as well as Isoflex in Australia, will be in higher demand. Second quarter pricing was down slightly more than our mid-single digit expectation due to greater than expected pressure on core legacy products.

    新有效成分呈現良好成長,但我們預期年對年增幅的大部分要到第四季才會出現,屆時 fluindapyr 在拉丁美洲與北美,以及 Isoflex 在澳洲的需求將更高。第二季定價下滑幅度略高於我們原先預期的中個位數,原因是核心既有產品承受的壓力大於預期。

  • Similar to prior quarters, there was more pronounced pricing pressure in LATAM and, to a lesser degree, Asia. New active ingredients and Cyazypyr delivered solid growth during the quarter, contributing to higher sales from our growth portfolio. Turning to slide 6, we reported second quarter EBITDA of $153 million, which was 2% above the high end of our guidance range, driven by greater than expected cost favorability. This was primarily driven by spend discipline in non-manufacturing areas and a few favorable quarter-specific items.

    與前幾季類似,拉丁美洲的定價壓力更為明顯,亞洲則在較小程度上受到影響。新有效成分與 Cyazypyr 在本季帶來穩健成長,推動我們成長型產品組合的銷售提升。接著看投影片6,我們第二季 EBITDA 為 1.53 億美元,較指引區間上緣高出 2%,主要受惠於成本表現優於預期。這主要來自非製造領域的支出紀律,以及少數對本季有利的特定項目。

  • Adjusted earnings per share of $0.26 was 62% lower than prior year due to the reduction in EBITDA and higher interest expense. The result was at the high end of our guidance range driven by EBITDA. Shifting to our forward guidance. Our updated financial outlooks are on slide 7 through 9. Starting with slide 7, full-year sales are now expected to be $3.5 billion to $3.7 billion, a decline of 7% at the midpoint.

    調整後每股盈餘為 0.26 美元,因 EBITDA 下滑與利息費用增加,較去年同期下降 62%。在 EBITDA 帶動下,結果落在我們指引區間的上緣。接著說明我們的前瞻指引。更新後的財務展望在投影片7到9。先看投影片7,全年銷售額目前預期為 35 億至 37 億美元,以中點計下降 7%。

  • We have updated our full-year outlook to reflect the more challenging market conditions we've seen so far this year. We now expect more pricing pressure and less volume growth of core legacy products than our prior forecast. Volume is now expected to be in line with prior year as sales of new active ingredients and increased direct sales to grow in Brazil offset reduced diamide partner orders.

    我們已更新全年展望,以反映今年迄今所見更具挑戰的市場狀況。我們現在預期定價壓力更大,且核心既有產品的銷量成長低於先前預測。目前預期銷量將與去年持平,因新有效成分的銷售與在巴西增加直銷的成長,可抵銷二醯胺合作夥伴訂單減少的影響。

  • Price is expected to decline mid to high single-digit, consistent with what we observed in the first half. The removal of India is a 2% headwind, and FX is expected to be a low single-digit tailwind. Adjusted EBITDA is now expected to be between $620 million and $680 million. The 23% decline at the midpoint reflects lower price and FX headwinds, partially offset by favorable costs.

    價格預期將下滑中到高個位數,與我們在上半年觀察到的情況一致。移除印度帶來 2% 的逆風,而匯率預期將帶來低個位數的順風。調整後 EBITDA 目前預期介於 6.2 億至 6.8 億美元。以中點計 23% 的降幅反映較低的價格與匯率逆風,部分由有利的成本所抵銷。

  • Adjusted EPS is expected to be between $1.19 and $1.49, with the 55% decline at the midpoint reflecting both lower EBITDA and higher interest expense. Given the uncertainty around the duration of the conflict in Iran and potential US trade actions, we continue to assume that the Iran-related cost pressures and tariff-related benefits largely offset each other. Turning to slide 8, we expect third quarter sales between $840 million and $900 million.

    調整後 EPS 預期介於 1.19 至 1.49 美元,以中點計下降 55%,反映 EBITDA 降低與利息費用增加。鑑於伊朗衝突持續時間的不確定性以及美國可能採取的貿易行動,我們仍假設與伊朗相關的成本壓力與關稅相關的效益大致互相抵銷。接著看投影片8,我們預期第三季銷售額介於 8.4 億至 9 億美元。

  • We expect the market conditions that we observed in the second quarter to persist in the third quarter. The majority of the 9% midpoint sales decline is due to price, which is expected to be a mid to high single-digit headwind. Volume is expected to be lower, mainly driven by North America distributors managing inventory by shifting orders from Q3 to Q4.

    我們預期第二季所觀察到的市場狀況將延續至第三季。以中點計 9% 的銷售下滑主要來自價格因素,預期將形成中到高個位數的逆風。銷量預期較低,主要因北美經銷商透過將訂單由第三季移至第四季來管理庫存。

  • In Brazil, we're continuing our strategy to lower our sales to distributors to favor co-ops and direct sales. This decision negatively impacts Q3 sales in favor Q4 sales. It reflects our intent to continue to stabilize the performance and predictability of Brazil's sales as we enter Q4 in 2027. We expect overall growth portfolio sales to increase in the quarter, driven by solid performance from new active ingredients.

    在巴西,我們持續推動降低對經銷商的銷售、轉而偏重合作社與直銷的策略。此決策對第三季銷售造成負面影響,但有利於第四季銷售。這反映我們的意圖:在邁入 2027 年第四季時,持續提升巴西銷售表現的穩定性與可預測性。我們預期本季整體成長型產品組合的銷售將增加,主要由新有效成分的穩健表現帶動。

  • Third quarter EBITDA is expected to be between $120 million and $140 million. This represents a 45% decline at the midpoint, driven mainly by lower price with volume and FX acting as some [unrealized] wins. Adjusted EPS is expected to be $0.05 and $0.13, a decline of 90% at the midpoint, driven by lower EBITDA and higher interest.

    第三季 EBITDA 預期介於 1.2 億至 1.4 億美元。以中點計下降 45%,主要由較低的價格所致,而銷量與匯率則帶來一些[尚未實現]的助益。調整後 EPS 預期為 0.05 至 0.13 美元,以中點計下降 90%,主要由 EBITDA 降低與利息增加所致。

  • Slide 9 provides our outlook for the fourth quarter, which we expect will represent a return to year-over-year growth. Sales are expected to be between $1.06 billion and $1.2 billion, an increase of 4% at the midpoint. We are not expecting major changes to market condition, and as such, we are forecasting a price decrease similar to the first three quarters in the mid to high single-digit. We are expecting strong volume growth, but it is not based on the assumption of sharp improvement in regional markets.

    投影片9提供我們對第四季的展望,我們預期將回到年對年成長。銷售額預期介於 10.6 億至 12 億美元,以中點計增加 4%。我們不預期市場狀況會有重大變化,因此我們預測價格降幅將與前三季相近,為中到高個位數。我們預期銷量將強勁成長,但並非基於區域市場出現明顯改善的假設。

  • About half of the volume growth is expected to come from increased sales in Brazil, driven by new products and a more established sales force, which has now been in place for over a year. The remaining half of fourth quarter growth is expected to come from new products as well as the shift in order timing by North America distributors from Q3 to Q4.

    約一半的銷量成長預期將來自巴西銷售增加,主要由新產品與更成熟的銷售團隊帶動,而該團隊目前已運作超過一年。第四季成長的其餘一半預期將來自新產品,以及北美經銷商將訂單時點由第三季移至第四季。

  • Fourth-quarter EBITDA is expected to be between $275 million and $315 million, representing 5% growth at the midpoint. Lower price and FX headwind are expected to be more than offset by favorable cost and higher volume. We're expecting strong cost favorability due to cost mitigation actions, including lower raw materials. Adjusted EPS is expected to be between $1.09 and $1.33. This represents a 1% increase at the midpoint as higher EBITDA more than offsets elevated interest expense.

    第四季 EBITDA 預計介於 2.75 億至 3.15 億美元之間,以中位數計算代表成長 5%。預期較低的價格與匯率(FX)逆風將被有利的成本因素與更高的銷量所抵銷且有餘。我們預期成本面將有強勁的有利因素,主要來自成本緩解措施,包括原物料成本下降。調整後 EPS 預計介於 1.09 美元至 1.33 美元之間。以中位數計算,這代表成長 1%,因較高的 EBITDA 足以抵銷偏高的利息費用。

  • I will now turn the call over to Andrew.

    我現在把電話會議交給 Andrew。

  • Andrew Sandifer - Chief Financial Officer, Executive Vice President

    Andrew Sandifer - Chief Financial Officer, Executive Vice President

  • Thanks, Pierre. I will start this morning with free cash flow in slide 10. Free cash flow in the second quarter was $357 million, $318 million higher than the prior year period. Included in free cash flow this quarter is the $200 million prepayment from Corteva as part of the licensing agreement for rimisoxafen that was finalized in June.

    謝謝你,Pierre。今天早上我將從第 10 頁投影片的自由現金流開始。第二季自由現金流為 3.57 億美元,較去年同期增加 3.18 億美元。本季自由現金流包含 Corteva 的 2 億美元預付款,該預付款為 6 月完成定案的 rimisoxafen 授權協議的一部分。

  • This payment is reflected in the change in other operating assets and liabilities net line on our cash flow statement, and as a long-term advanced payment liability on our balance sheet. As a result, it does not impact working capital. While the specific structure of the rimisoxafen licensing agreement may not recur, we expect licensing and collaboration agreements to remain a part of our business model and an important contributor to operating cash flow over time.

    此筆款項反映在我們現金流量表中的「其他營運資產及負債變動(淨額)」項下,並在資產負債表中列為長期預收款負債。因此,它不會影響營運資金。雖然 rimisoxafen 授權協議的特定架構未必會再度出現,但我們預期授權與合作協議將持續是我們商業模式的一部分,並在長期內成為營運現金流的重要貢獻來源。

  • We intend to pursue additional opportunities to license molecules from our portfolio and to enter collaborations that allow us to share the cost of developing earlier-stage active ingredients. The reality is that our pipeline contains more high-quality active ingredients than we can fund and develop in a timely manner on our own.

    我們打算尋求更多機會,將我們產品組合中的分子進行授權,並建立合作關係,以便分攤開發較早期有效成分的成本。現實是,我們的研發管線中高品質有效成分的數量,超過我們能夠自行及時投入資金並完成開發的範圍。

  • As a result, partnerships such as our licensing agreements with Corteva for rimisoxafen and fluindapyr, and with Bayer for Isoflex active, as well as future co-development arrangements, are becoming an increasingly important part of our operating model. These collaborations help accelerate the development and commercialization of new technologies while also providing a meaningful source of operating cash generation.

    因此,像是我們與 Corteva 就 rimisoxafen 與 fluindapyr 的授權協議、與拜耳(Bayer)就 Isoflex active 的授權協議,以及未來的共同開發安排,正成為我們營運模式中愈來愈重要的一環。這些合作有助於加速新技術的開發與商業化,同時也提供具實質意義的營運現金創造來源。

  • Beyond the prepayment from Corteva, free cash flow in the second quarter also benefited from lower receivables overall, with strong collections in Asia, including India and in EMEA, as well as lower cash taxes. We are updating our 2026 free cash flow outlook to reflect both the updated EBITDA outlook and the Corteva prepayment. We now expect free cash flow to be in the range of $75 million to $225 million, or $150 million at the midpoint.

    除了 Corteva 的預付款之外,第二季自由現金流也受惠於整體應收帳款下降,亞洲(包括印度)以及 EMEA 地區的收款表現強勁,並且現金稅負較低。我們正在更新 2026 年自由現金流展望,以反映更新後的 EBITDA 展望以及 Corteva 的預付款。我們目前預期自由現金流將介於 7,500 萬至 2.25 億美元之間,中位數為 1.5 億美元。

  • Our free cash flow guidance also includes approximately $170 million in expected cash spending on restructuring, driven largely by the significant reshaping of our manufacturing and supply network that is underway. Free cash flow excluding restructuring would be approximately $320 million in 2026 at the guidance midpoint.

    我們的自由現金流指引亦包含約 1.7 億美元的預期重整現金支出,主要由目前進行中的製造與供應網路大幅重塑所驅動。若排除重整影響,2026 年在指引中位數下的自由現金流約為 3.2 億美元。

  • While we do expect to have meaningful continued cash spending on restructuring in 2027, this should dramatically reduce in 2028 and beyond, greatly improving our free cash flow generation. Moving next to the balance sheet and leverage. The second quarter was a particularly active quarter on the financing front. In mid-April, we amended our existing revolving credit facility.

    雖然我們確實預期 2027 年仍將有相當程度的重整現金支出,但在 2028 年及之後應會大幅降低,從而顯著改善我們的自由現金流創造能力。接著談資產負債表與槓桿。第二季在融資方面特別活躍。4 月中旬,我們修訂了既有的循環信用額度(revolving credit facility)。

  • In May, we completed a $1.2 billion senior secured bond offering. We were pleased with the strong demand for the offering. Significant oversubscription allowed us to meaningfully increase the size and reduce the rate of the offering from launch. Proceeds from the bond offering were used to redeem the $500 million in senior notes that were due to mature in October, as well as to reduce borrowings under our revolver.

    5 月,我們完成了 12 億美元的優先擔保債券發行。我們對本次發行的強勁需求感到滿意。顯著超額認購使我們得以在發行啟動後,大幅提高發行規模並降低利率。本次債券發行所得款項用於贖回原定於 10 月到期的 5 億美元優先票據,並降低我們在循環信貸項下的借款。

  • We ended the second quarter with gross debt of approximately $4.3 billion, down $250 million from the prior quarter end. Cash on hand increased $86 million to $477 million, resulting in net debt of approximately $3.8 billion, down $339 million from the prior quarter end. Net debt to trailing 12-month EBITDA was 5.1x. As we described on the April call, the most recent amendment to our revolving credit agreement included changes to our covenant leverage metrics.

    第二季末我們的總負債約為 43 億美元,較前一季季末減少 2.5 億美元。手上現金增加 8,600 萬美元至 4.77 億美元,使淨負債約為 38 億美元,較前一季季末減少 3.39 億美元。淨負債對過去 12 個月 EBITDA 的比率為 5.1 倍。如同我們在 4 月電話會議中所述,最近一次對循環信貸協議的修訂包含對契約(covenant)槓桿衡量指標的變更。

  • The maximum total leverage ratio is not measured formally for the second or third quarters under the terms of the amendment, but would've been approximately 5.6x. The maximum total leverage covenant will be reinstated in the fourth quarter at 6.75x through December 31, 2027. Secured debt to trailing 12-month EBITDA was 1.66x as compared to a covenant limit of 3.5x.

    依修訂條款,第二季或第三季不會正式衡量最高總槓桿比率,但若計算約為 5.6 倍。最高總槓桿契約將於第四季恢復適用,並在 2027 年 12 月 31 日前維持在 6.75 倍。擔保負債對過去 12 個月 EBITDA 的比率為 1.66 倍,相較於契約上限 3.5 倍。

  • Minimum interest coverage ratio was 2.78x as compared to a covenant minimum of 2.0x. Looking now at year-end debt levels. Based on our free cash flow guidance, together with proceeds from the India sale, Delaware site sale leaseback, and the Tessenderlo equity investment, and after reflecting dividends, financing fees, and transaction costs, we expect to end 2026 with net debt of approximately $2.6 billion.

    最低利息保障倍數為 2.78 倍,相較於契約最低要求 2.0 倍。接著看年底負債水準。根據我們的自由現金流指引,加上印度出售案、Delaware 廠址出售後回租,以及 Tessenderlo 的股權投資所得款項,並在反映股利、融資費用與交易成本後,我們預期 2026 年底淨負債約為 26 億美元。

  • At the midpoint of our EBITDA guidance, this would suggest year-end 2026 net debt to trailing 12-month EBITDA of roughly 4x. While this is still meaningfully higher than where we would like to be long term, we believe FMC will be well-positioned to further improve leverage metrics as we return to EBITDA growth in 2027 and maintain a relentless focus on driving free cash flow from the business.

    以我們 EBITDA 指引的中位數計算,這意味著 2026 年底淨負債對過去 12 個月 EBITDA 的比率約為 4 倍。雖然這仍明顯高於我們長期希望達到的水準,但我們相信,隨著 2027 年 EBITDA 恢復成長,並持續以不懈的專注推動業務自由現金流,FMC 將具備良好條件進一步改善槓桿指標。

  • As a result of the financing actions completed in the quarter, we have substantial available liquidity. Borrowings under our revolving credit facility were $250.5 million at June 30th. With letters of credit backed by the revolver of $188.6 million, we had more than $1.56 billion of borrowing capacity available under our revolver at quarter end. We are comfortably in compliance with our covenant metrics. Our next bond maturity is three years away, with $500 million in notes due in October 2029.

    由於本季完成的融資行動,我們擁有充足的可用流動性。截至 6 月 30 日,我們在循環信用額度項下的借款為 2.505 億美元。在以循環信貸作為擔保的信用狀金額 1.886 億美元之下,季末我們在循環信貸項下仍有超過 15.6 億美元的可用借款額度。我們在契約指標方面均能輕鬆符合要求。我們下一筆債券到期日在三年後,為 2029 年 10 月到期的 5 億美元票據。

  • We feel confident that all of the financing and strategic actions we are taking this year are greatly strengthening the financial foundation of the company. Lastly, moving to the income statement. Second quarter sales benefited from a 2% currency tailwind, primarily coming from strengthening of the Brazilian real.

    我們有信心,今年我們所採取的所有融資與策略行動,正大幅強化公司的財務基礎。最後,談到損益表。第二季銷售受惠於 2% 的匯率順風,主要來自巴西雷亞爾走強。

  • Looking ahead, we expect FX to move from being a tailwind in the first half to being relatively neutral in the second half, resulting in a low single-digit FX impact on revenue for the full year. Second quarter interest expense of $71.3 million was up $10 million, with the impact of financing activity in the quarter partially offset by interest income and lower foreign interest expense.

    展望未來,我們預期匯率將從上半年的順風轉為下半年相對中性,使全年營收的匯率影響為低個位數。第二季利息費用為 7,130 萬美元,增加 1,000 萬美元;其中本季融資活動的影響,部分被利息收入以及較低的海外利息費用所抵銷。

  • We now expect full year 2026 interest expense to be in the range of $275 million-$285 million, up approximately $40 million versus the prior year at the midpoint due to the impacts of the recent financing activity, partially offset by lower foreign interest expense. We continue to expect depreciation in amortization for full year 2026 to be between $160 million and $170 million.

    我們目前預期 2026 全年利息費用將落在 2.75 億至 2.85 億美元之間,以中位數計算較前一年增加約 4,000 萬美元,主要因近期融資活動的影響,部分被較低的海外利息費用所抵銷。我們仍預期 2026 全年折舊與攤銷費用將介於 1.6 億至 1.7 億美元之間。

  • The effective tax rate on adjusted earnings in the second quarter was 17%, in line with our expected full-year effective tax rate of 16%-18%. With that, I'll hand the call back to Pierre.

    第二季調整後盈餘的有效稅率為 17%,與我們對全年有效稅率 16%–18% 的預期一致。接下來我把電話交回給 Pierre。

  • Pierre Brondeau - Chairman of the Board, Chief Executive Officer

    Pierre Brondeau - Chairman of the Board, Chief Executive Officer

  • Thank you, Andrew. To close, the 2026 market environment will continue to be challenging. We're using these challenging conditions to improve the performance of some critical countries by repositioning their business. We are strengthening FMC's financial foundation, advancing the actions tied to operational peers, and maintaining a clear focus on execution.

    謝謝你,Andrew。最後總結,2026 年的市場環境仍將充滿挑戰。我們正利用這些艱難條件,透過重新定位其業務,來改善一些關鍵國家的表現。我們正在強化 FMC 的財務基礎,推進與營運同業對標相關的行動,並持續清楚聚焦於執行。

  • The work underway will allow our core business to become competitive again, while our new technology portfolio becomes a larger part of the company. The work underway in 2026 will position FMC to return to growth as early as 2027 and beyond.

    目前進行中的工作將使我們的核心業務重新具備競爭力,同時讓我們的新技術產品組合在公司中占比更大。2026 年正在推進的工作將使 FMC 最早在 2027 年及之後重回成長軌道。

  • With that, we are happy to take your questions.

    接下來,我們很樂意回答各位的問題。

  • Operator

    Operator

  • (Operator Instructions) Duffy Fischer, Goldman Sachs.

    (接線員指示) Duffy Fischer,高盛。

  • Duffy Fischer - Analyst

    Duffy Fischer - Analyst

  • Good morning, guys. First question is just around the ramp from your Q3 midpoint to your Q4 midpoint, kind of $165 million of improvement. Can you walk through sequentially what those buckets are? What are the big drivers? Because again, margin goes from like 15% in Q3 to over 25% in Q4.

    各位早安。第一個問題是關於從你們第三季指引中位數到第四季指引中位數的爬坡,改善大約 1.65 億美元。你們能否按序說明這些項目分別是哪些?主要驅動因素是什麼?因為同樣地,毛利率從第三季大約 15% 提升到第四季超過 25%。

  • Give some qualitative indication, just how certain are you of those buckets? Do you have orders in hand? Is it based on just kind of historic norm repeating itself? Just try to help us get comfortable with that big ramp up from Q3 to Q4.

    也請給一些定性說明:你們對這些項目的把握度有多高?你們手上已有訂單嗎?還是主要基於歷史常態的重現?請協助我們對第三季到第四季這個大幅爬坡更有信心。

  • Pierre Brondeau - Chairman of the Board, Chief Executive Officer

    Pierre Brondeau - Chairman of the Board, Chief Executive Officer

  • Thanks, Duffy. Let me try to go from Q3 to Q4. Three big drivers on the positive front. First, the non-diamide core, and that includes the growth, of course, in direct sales in Brazil. We're expecting this to be about $150 million. The new active ingredients. We believe with the number we see now forecasting, it's going to be from Q3 to Q4, about $70 million.

    謝謝,Duffy。我試著從第三季到第四季來說明。正面因素有三個主要驅動。第一,非二醯胺核心業務,當然也包含巴西直銷的成長。我們預期這部分約為 1.5 億美元。第二,新有效成分。依我們目前看到的預測數字,從第三季到第四季大約是 7,000 萬美元。

  • Then you have others, including brand Rynaxypyr, especially in Latin America, in the range of $40 million. When you go from Q3 to Q4, those three buckets, less technical sales. As you know, we have less buy from partners for diamides. We get to a number which is an increase in the range of $260 million. The non-diamide core I talk about, it's largely driven by the normal seasonality.

    接著是其他項目,包括 Rynaxypyr 品牌,特別是在拉丁美洲,約 4,000 萬美元。從第三季到第四季,這三個項目合計,再扣除技術性銷售。如各位所知,我們從合作夥伴端購買二醯胺的量較少。因此我們得到的數字是增加約 2.6 億美元的區間。我提到的非二醯胺核心業務,主要是由正常的季節性所驅動。

  • Usually, and historically, you see an increase from Q3 to Q4 of about 15%. That is, in addition, it's a bit higher this time because we do our increasing our direct sales in Brazil. As you've heard in the script, we have a shift in North America of sales from Q3 to Q4.

    通常且從歷史來看,你會看到第三季到第四季約 15% 的增幅。此外,這次會更高一些,因為我們正在提高巴西的直銷比重。如你在講稿中聽到的,我們在北美也有把銷售從第三季移轉到第四季的情況。

  • The second-largest driver is the new active ingredients, and that is going to be mostly fluindapyr in North America and Isoflex in Australia and diamide, Plant Health, all the rest. That's roughly the bridge from Q3 to Q4, which go from seasonality to specific actions we are taking, like direct sales or new active ingredients.

    第二大驅動因素是新有效成分,主要會是北美的 fluindapyr、澳洲的 Isoflex,以及二醯胺、植物健康等其他項目。這大致就是第三季到第四季的銜接,從季節性到我們正在採取的具體行動,例如直銷或新有效成分。

  • Operator

    Operator

  • Edlain Rodriguez, Mizuho Securities.

    Edlain Rodriguez,瑞穗證券。

  • Edlain Rodriguez - Analyst

    Edlain Rodriguez - Analyst

  • Thank you, and good morning, everyone. Pierre, I kind of wanted to ask you something about more medium and longer term. Clearly, 2026 is a transition year. As you navigate the changes and action you are undertaking to improve the portfolio, it seems like it's a process where things can get worse before they get better, but in the end, you will come out stronger.

    謝謝,大家早安。Pierre,我想問一個偏中期與長期的問題。很明顯 2026 年是過渡年。當你們推動變革並採取行動以改善產品組合時,看起來這是一個在變好之前可能先變得更糟的過程,但最終你們會以更強的姿態走出來。

  • The question is, with the things you can control, when do you think we will start to see the benefits of the work you are doing? Essentially, how does the patient get better going forward?

    問題是,就你們可控的部分而言,你認為我們何時會開始看到你們正在做的工作所帶來的效益?本質上,接下來「病人」會如何好轉?

  • Pierre Brondeau - Chairman of the Board, Chief Executive Officer

    Pierre Brondeau - Chairman of the Board, Chief Executive Officer

  • Yes. Thank you. Listen, I believe at this stage, that's a discussion we're having here often and often. As we look at it, we have all the reasons in the world to believe that 2026 is the trough. We believe the worst is behind us with the loss of IP protection on Rynaxypyr. For Rynaxypyr, all signs are pointing to us being able to protect Rynaxypyr earnings in 2027.

    是的。謝謝。聽著,我認為在這個階段,這是我們在這裡一再討論的話題。就我們的觀察而言,我們有充分理由相信 2026 年是谷底。隨著 Rynaxypyr 的智慧財產保護到期所帶來的影響,我們認為最糟的情況已經過去。就 Rynaxypyr 而言,各項跡象都指向我們有能力在 2027 年守住 Rynaxypyr 的獲利。

  • If you assume that, I'm looking at four critical things which will be starting to make 2027 the first growth year. First, let's talk about our biggest issue in 2026. This is a $2.1 billion non-diamide core business, and that business is down this year or should be down when we close the year by about 5%.

    在此假設下,我關注四個關鍵事項,它們將開始使 2027 年成為第一個成長年度。首先,談談我們在 2026 年最大的問題。這是一個 21 億美元規模的非二醯胺核心業務,而該業務今年下滑,或在年底結束時應會下滑約 5%。

  • With all the work we are doing on a global manufacturing footprint, we should be competitive again and back to growth as soon as next year. If we only assume to get back to an annual growth of 1% or 2%, which should be below market, it's fairly modest. If you compare to being down 5% this year, this is an incremental sales of about $120 million-$150 million.

    透過我們在全球製造佈局上的所有工作,我們應能重新具備競爭力,並最快在明年恢復成長。即便只假設回到每年 1% 或 2% 的成長率(這應低於市場成長),其實相當保守。若與今年下滑 5% 相比,這相當於新增銷售額約 1.2 億至 1.5 億美元。

  • That's the first bucket. Just linked to the work we do on a manufacturing footprint. On bucket number two is our new active ingredients. The growth should be accelerating to a minimum of 50%-70% as we are gaining more and more registration. If you look at the expected size of our new active ingredients, that would be in 2027 versus 2026, an additional $150 million-$200 million.

    這是第一個項目。主要與我們在製造佈局上的工作直接相關。第二個項目是我們的新有效成分。隨著我們取得越來越多的登記核准,成長應會加速,至少達到 50%–70%。若看我們新有效成分的預期規模,2027 年相較 2026 年將額外增加 1.5 億至 2 億美元。

  • Branded sales appear steady as she go, should continue its mid-single digit growth. It's an additional $20 million. Last point, this one I have not qualified. You know we keep on shifting more and more of our sales business in Brazil toward co-ops and direct sales. This also should represent a growth, but we are not quantifying it yet because, as you know, we are controlling our sales toward the more traditional distribution network.

    品牌銷售看起來穩健,應可持續中個位數成長。這會額外增加 2,000 萬美元。最後一點,這部分我尚未量化。你們知道我們持續把巴西的銷售業務更多地轉向合作社與直銷。這也應代表成長,但我們尚未量化,因為如你們所知,我們正在控制對較傳統經銷網路的銷售。

  • We need to balance the growth in co-ops and direct sales versus the decrease in the more traditional network. That's more of a budget exercise, not yet capable of controlling that. On the negative front, we'll still have some negative impacts of diamide sales to partners. It will be getting smaller and smaller, and this segment is getting smaller and most of the cost decrease for Rynaxypyr has taken place.

    我們需要在合作社與直銷的成長,和較傳統通路的下滑之間取得平衡。這比較像是預算上的推演,目前還不具備完全控制的能力。負面方面,我們對合作夥伴的二醯胺(diamide)銷售仍會有一些負面影響。這個影響會愈來愈小,該區隔也在縮小,而且 Rynaxypyr 的大部分成本下降已經發生。

  • If you look at that without quantifying the last bucket around Brazil, this is natural growth of $300 million-$350 million in 2027 versus 2026. That should keep on improving as we grow, as the new active ingredients will be getting more and more traction.

    如果你看這個(先不量化最後一個與巴西相關的項目),2027 年相較 2026 年的自然成長約為 3 億至 3.5 億美元。隨著我們成長,這應該會持續改善,因為新的有效成分會獲得愈來愈多的市場採用。

  • As you say, the patient should get better quickly. We believe 2027, all indications are pointing toward a return to growth next year.

    如你所說,病人應該會很快好轉。我們相信 2027 年,所有跡象都指向明年將重回成長。

  • Operator

    Operator

  • Frank Mitsch, Fermium Research.

    Frank Mitsch,Fermium Research。

  • Frank Mitsch - Analyst

    Frank Mitsch - Analyst

  • Thank you, and good morning. Hey, Pierre, I wanted to drill on slide 5, the breakdown by the regions. North America came down fairly significantly. You mentioned a competitive market in North America. I was wondering if you could expand upon that. Where specifically, and how sustainable is that competitive market, and how we should think about that in the future. Thank you.

    謝謝,早安。嗨,Pierre,我想深入問一下第 5 頁投影片,按地區拆分的情況。北美下滑得相當明顯。你提到北美市場競爭激烈。我想請你再多展開說明一下。具體是哪些地方?這種競爭態勢有多可持續?以及我們未來應該如何看待?謝謝。

  • Pierre Brondeau - Chairman of the Board, Chief Executive Officer

    Pierre Brondeau - Chairman of the Board, Chief Executive Officer

  • Yeah. Thanks, Frank. You're absolutely right, North America was down. It is the negative news of the quarter for us. There is multiple drivers. They all went the wrong way. First, above all, it's a volume story. As you know, in North America, we are very strong in specialty crops with our insecticide business. Rice production was at the lowest level since 1987. That's a big market for us.

    是的。謝謝你,Frank。你說得完全正確,北美確實下滑。這是我們本季的負面消息。原因有好幾個。而且都往不利方向發展。首先也是最重要的,這是量的問題。如你所知,在北美,我們的殺蟲劑業務在特用作物上非常強。稻米產量降到 1987 年以來最低。那對我們來說是很大的市場。

  • Very low insect pressure, so we lost a lot of sales in specialty crops. Row crops is less of a market for us, but still important. It is absolutely certain that low margin at the growers level, high uncertainty. This is translating into growers managing their cost as much as possible. You see some trading from more branded products to generic product, and in some cases, skipping applications.

    害蟲壓力非常低,所以我們在特用作物上流失了大量銷售。大田作物對我們而言市場較小,但仍然重要。可以非常確定的是,種植戶端利潤偏低、不確定性很高。這使得種植戶盡可能地控管成本。你會看到部分需求從品牌產品轉向學名(generic)產品,某些情況下甚至會跳過施用。

  • Yes, Q2 was, from a volume standpoint, a very negative quarter. There is something to a less extent, but we have a license on a product, an herbicide, which is called pyroxasulfone. The company which own this license, it's only a license we have for North America, lost their IP protection. That product became more of a generic product, and we lost sales in that.

    是的,從銷量角度看,第二季是非常負面的季度。另外還有一件事,程度較小:我們在一個產品上有授權,是一款名為 pyroxasulfone 的除草劑。擁有該授權的公司——我們在北美只有授權——失去了其智慧財產權保護。該產品變得更像學名產品,我們在那上面流失了銷售。

  • Not sales, but we lost on pricing a lot, and also on volume on this product. I would say by far the number-one driver in North America, in addition to some pricing, but the number-one driver for the reason I just listed are volume.

    不是銷售額,而是我們在這個產品上價格下滑很多,同時銷量也下滑。我會說,北美最主要的驅動因素,除了部分定價因素之外,但我剛才列出的原因中最主要的驅動因素是銷量。

  • Operator

    Operator

  • Chris Parkinson, Wolfe Research.

    Chris Parkinson,Wolfe Research。

  • Chris Parkinson - Equity Analyst

    Chris Parkinson - Equity Analyst

  • Great. Thank you so much. Hi, Pierre. We take a step back, we look at the intermediate to longer-term growth in diamides. Perhaps could you just update us on what you think the overall growth rate is, including all new entrants in terms of the transitory period that we're currently in? Which other insecticide classifications we're stealing share from?

    很好。非常感謝。嗨,Pierre。我們退一步看,觀察二醯胺(diamides)中期到長期的成長。也許你能更新一下你對整體成長率的看法,包括目前這段過渡期內所有新進入者的影響?我們正在從哪些其他殺蟲劑分類中搶占市占?

  • Is it organophosphates, carbamates, neonicotinoids? Just how you think about the overall TAM there, because it seems like the market trajectory is still growth and that there's just basically competitive behaviors in the beginning of that process. If you could just hit on the highlights there from your own perspective, it would be greatly appreciated. Thank you.

    是有機磷、氨基甲酸酯、新菸鹼類嗎?你如何看待那裡的整體 TAM(可服務總市場),因為看起來市場軌跡仍在成長,只是在過程初期出現一些競爭行為。如果你能從你的角度談一下重點,我會非常感謝。謝謝。

  • Pierre Brondeau - Chairman of the Board, Chief Executive Officer

    Pierre Brondeau - Chairman of the Board, Chief Executive Officer

  • Thanks, Chris. Yes. I'm going to speak carefully here because we have a strategy in place for Rynaxypyr. As I said before, the big test will be in Q3, Q4, when we're going to have the major market with the entrance of new generics in Latin America and North America. We're not yet there. I'm talking about Q1 and Q2 indicators on much lower market.

    謝謝你,Chris。是的。我會謹慎地回答,因為我們對 Rynaxypyr 已有既定策略。如我先前所說,最大的考驗會在第三季、第四季,屆時拉丁美洲與北美將有新的學名產品進入,主要市場會受到影響。我們現在還沒到那一步。我談的是第一季與第二季在市場規模較小時的指標。

  • I would say that the number one sign of success we are looking in a strategy is the mix of a portfolio, as we were expecting, is shifting toward the high-end product. We are growing very fast on the new mixtures we have, especially the bifenthrin and Rynaxypyr mixture, as well as the high-concentration products. 35% growth in that sector, that's what we're expecting. We command a premium for those products, so it's a first positive.

    我會說,我們在策略上尋求成功的第一個訊號,是產品組合的結構如我們預期,正朝向高端產品移動。我們的新複配產品成長非常快,尤其是 bifenthrin 與 Rynaxypyr 的複配,以及高濃度產品。在那個領域成長 35%,這正是我們所預期的。我們對這些產品有溢價能力,所以這是第一個正面訊號。

  • We are seeing some sign that the market is growing, we've seen that in Brazil, where we are gaining toward lower-end insecticide. That is at the very beginning of the process. I think the big test is going to take place in the second half of the year. We do have some signal we've seen on Brazil.

    我們看到一些市場正在成長的跡象,我們在巴西看到了:我們正在從較低端的殺蟲劑那邊取得份額。這才剛開始。我認為真正的考驗會在下半年發生。我們確實在巴西看到一些訊號。

  • Product on the ground against some of those insecticide has been strong in the first half of the year. Again, on small volume. Indicators are good that the strategy with the lower cost we have reached and the strategy to move to our higher end. Certainly, we are not expecting at the earnings level Rynaxypyr in the long term to be a contributor to earnings growth for the company.

    上半年在田間端的產品表現,對上其中一些殺蟲劑時相當強勁。同樣地,量還不大。各項指標顯示,我們已達成的降成本,以及將組合往高端移動的策略,是有效的。當然,從長期來看,我們並不預期 Rynaxypyr 在獲利層面會成為公司獲利成長的貢獻者。

  • I would say that all indicators are pointing between the mix change and what we see at this stage of volume gain on the lower insecticide towards stabilizing earnings certainly in 2027. That is all I can say today in terms of what we are able to verify on the market.

    我會說,所有指標——包括組合變化,以及我們在此階段看到在較低端殺蟲劑上的銷量增長——都指向 2027 年獲利將趨於穩定。就我們目前能在市場上驗證的部分,我今天能說的就這些。

  • Operator

    Operator

  • Joel Jackson, BMO Capital Markets.

    Joel Jackson,BMO Capital Markets。

  • Joel Jackson - Equity Analyst

    Joel Jackson - Equity Analyst

  • Good morning, Pierre and team. Pierre, when you did all the actions over the last bunch of months, and you were aggressive, you did a lot of things. It seemed like you thought you could hold earnings around $700 million EBITDA with the free cash flow around that. You have come down a little bit lower this year, leverage a little bit higher than maybe what you would have thought.

    早安,Pierre 與團隊各位。Pierre,過去幾個月你採取了所有行動,而且相當積極,做了很多事情。看起來你原本認為可以把獲利維持在約 7 億美元 EBITDA,且自由現金流也大致在那個水準。今年你們的水準下修了一些,槓桿也比你可能原先預期的略高。

  • What other actions? Do you feel that you should wait for 2027, need to get the rebound you have been talking about earlier on this call, or are there other things you want to do? Might you consider cutting the dividend, doing things to protect the balance sheet some more in this 2026 being a bit lower than thought?

    還有其他行動嗎?你覺得是否應該等到 2027 年、需要在這通電話先前提到的反彈出現,還是你們還想做其他事情?鑑於 2026 年可能比原先想的更低,你們會考慮削減股利、採取更多保護資產負債表的措施嗎?

  • Pierre Brondeau - Chairman of the Board, Chief Executive Officer

    Pierre Brondeau - Chairman of the Board, Chief Executive Officer

  • I am going to let Andrew talk about cash flow and what we do in terms of additional actions we are planning for next year. I am only going to answer the last point you have made around dividend. As you know, our dividend are small. It is certainly a topic we will have with the Board and continue to have with the Board. It is a $50 million cost annually. No decision, absolutely no decision has been taken at this stage in terms of the dividend.

    我先讓 Andrew 談談現金流,以及我們針對明年規劃的額外行動。我只回答你最後一點關於股利的問題。如你所知,我們的股利金額不大。這當然是我們會與董事會討論、並持續與董事會討論的議題。每年成本是 5,000 萬美元。截至目前,關於股利尚未做出任何決定,絕對沒有做出任何決定。

  • Andrew, if you want to add anything.

    Andrew,如果你想補充什麼的話。

  • Andrew Sandifer - Chief Financial Officer, Executive Vice President

    Andrew Sandifer - Chief Financial Officer, Executive Vice President

  • Sure. I think, look, Joel, on the free cash flow side, obviously we updated the free cash flow guidance with the change in EBITDA guidance and with the rimisoxafen licensing deal. There are more moving parts in that. Just to touch on that briefly as I address your question. From a cash from operations perspective, net net, we moved the guidance midpoint up $85 million.

    好的。我想,Joel,就自由現金流而言,我們顯然已隨著 EBITDA 指引的變動以及 rimisoxafen 授權交易,更新了自由現金流指引。其中有更多變動因素。我在回答你的問題時,先簡要提一下。從營運活動現金流的角度來看,整體而言,我們把指引中位數上調了 8,500 萬美元。

  • That's about $200 million from the rimisoxafen deal. Obviously some headwinds hitting against that, certainly the biggest being the lower EBITDA expectation. We also have some higher restructuring spending as we're accelerating some of our actions to improve our manufacturing network. We do see a little less improvement in working capital this year because of the sales shift from Q3 to Q4. There's a few other minor drags as well.

    其中約 2 億美元來自 rimisoxafen 交易。當然也有一些逆風抵銷,最大的一項無疑是較低的 EBITDA 預期。此外,因為我們正在加速部分改善製造網路的行動,重整支出也更高。由於銷售從第三季移轉到第四季,我們也看到今年營運資金改善幅度略小。另外還有一些其他較小的拖累因素。

  • From a CapEx perspective, with accelerating some of those movements on our manufacturing footprint, we were able to reduce the expected CapEx for the year by about $40 million. Our outlook for discontinued operations is unchanged. We did highlight we'll be pulling out certain charges that are related to transactions that flow through the restructuring line. We'll pull that out from free cash flow under divestiture expenses.

    從資本支出(CapEx)的角度來看,隨著我們加速製造版圖的部分調整,我們得以把今年預期的資本支出下調約 4,000 萬美元。我們對已終止營運的展望沒有改變。我們也特別指出,會把某些與交易相關、但會流經重整科目的費用剔除。我們會在自由現金流中,將其列為處分費用(divestiture expenses)予以剔除。

  • The net of those changes is really just, on a like-for-like basis, a $50 million reduction in the free cash flow for the year. I do think, again, from a working capital perspective, back to part of your question here, we do expect a release from working capital this year, in part from liquidation of receivables in our India business, but in part from the rest of our business.

    這些變動加總後,實際上在可比基礎下,今年自由現金流減少 5,000 萬美元。我也認為,再回到你問題的一部分,從營運資金角度來看,我們確實預期今年會有營運資金釋放,一部分來自印度業務應收款的回收(liquidation),另一部分則來自我們其餘業務。

  • We have more work to do on improving working capital as we continue to get into a better rhythm with our production cadence, as we continue to drive a more aggressive collection of receivables, and improving overall credit quality of the portfolio. I think you'll see this year some good improvement in inventory reduction as we get through the year. More work to do on receivables and payables as we go into 2027.

    隨著我們在生產節奏上持續進入更好的運作韻律、持續更積極地催收應收款、並提升整體投組的信用品質,我們在改善營運資金方面還有更多工作要做。我想你會看到今年隨著年度推進,庫存降低會有不錯的改善。至於應收與應付,進入 2027 年時仍有更多工作要做。

  • Pierre Brondeau - Chairman of the Board, Chief Executive Officer

    Pierre Brondeau - Chairman of the Board, Chief Executive Officer

  • I think, Joel, let me build a little bit on what Andrew just said, because it's one of the very critical parts of our balance sheet. You will see this year it's something we fully control, it's inventory, and we do have strong expectation that we're going to make some very significant progress on the inventory situation. We are monitoring that very closely, and all indicators are pointing to a strong progress.

    Joel,我想在 Andrew 剛才說的基礎上再補充一點,因為這是我們資產負債表非常關鍵的一部分。你今年會看到一件我們完全可控的事情,就是庫存;我們非常有信心能在庫存狀況上取得非常顯著的進展。我們正非常密切地監控,所有指標都顯示進展強勁。

  • The place where we have work to do, we are starting it this year, it's going to be very important next year, is on receivable. It's very much part of the strategy we have in Brazil, and we've talked about the move toward customers which have more certainty of paying, less slow-moving and better terms like co-ops and direct sales, that some of the, I would call consolidated distribution network, which is becoming much more uncertain.

    我們需要努力的地方——我們今年已開始著手、且明年會非常重要——是在應收款方面。這是我們在巴西策略的重要一環;我們也談過要轉向付款確定性更高、周轉較不慢、條件更好的客戶,例如合作社(co-ops)與直銷,而不是某些我稱之為整合型分銷網路的客戶,因為那正變得更不確定。

  • It's one area of focus. Maybe not as much progress this year as we would like, but certainly we are making that a very high priority. We should see very strong improvement as we are changing a mix of customer, especially in Latin America and Brazil next year.

    這是其中一個重點領域。今年的進展或許沒有我們希望的那麼多,但我們確實把它列為非常高的優先事項。隨著我們明年改變客戶組合,特別是在拉丁美洲與巴西,我們應該會看到非常明顯的改善。

  • Operator

    Operator

  • Patrick Cunningham, Citi.

    Patrick Cunningham,花旗。

  • Patrick Cunningham - Analyst

    Patrick Cunningham - Analyst

  • Hi, good morning. Just a couple of questions on the cost side. I think you mentioned at the top of the call some quarter-specific items that benefit the cost. I guess first, what were those? Were those some cost saves pulled forward? Then can you quantify what the headwinds, tailwinds might be for the second half?

    嗨,早安。關於成本端我有幾個問題。我想你在電話會議一開始提到一些特定季度的項目,對成本有利。我想先問,那些是什麼?那些是把一些節省成本提前認列嗎?另外,你能量化一下下半年可能的逆風與順風嗎?

  • Andrew Sandifer - Chief Financial Officer, Executive Vice President

    Andrew Sandifer - Chief Financial Officer, Executive Vice President

  • Sure, Patrick, it's Andrew. I'll take this one. Look, in Q2, comment we made relative to guidance, we had some improved cost favorability in non-manufacturing items. Some of that's SG&A and R&D. Some of it, quite honestly, is just some smaller items that generally we wouldn't talk about, but we had a couple things that were positive in the quarter, and they contributed. I'll give you a simple example.

    好的,Patrick,我是 Andrew。這題我來回答。你看,在第二季,相對於指引我們提到的是:在非製造項目上,成本有一些改善的有利因素。其中一部分是 SG&A 與研發(R&D)。另外坦白說,也有一些通常我們不會特別提的小項目,但本季有幾件正面因素,確實有所貢獻。我給你一個簡單例子。

  • We annually review our [shipment] reserve, which is essentially think of uncashed checks and other kind of liabilities, and we found that we were over-accrued based on what was actually due and outstanding. There are a few minor little favorable things like that, but when they add up, they were an adverse to guidance in terms of our cost position.

    我們每年會檢視一次我們的[shipment]準備金(reserve),基本上可把它理解為未兌現支票及其他類型負債;我們發現依據實際到期與未清償金額來看,我們先前提列過多。還有幾個像這樣的小幅有利因素;但加總起來,它們在成本表現上相對於指引是有利的。

  • I think when we look at costs for the remainder of the year, we do have a bit of two different stories with the quarters. In the third quarter, we really don't have much of a cost tailwind. You'll remember that that's a really tough quarter comp versus the prior year. We had a very strong cost tailwind in the prior year period in Q3, much of which was one-time favorability from accrued cost volume absorption in Q3 of 2025.

    我想當我們看今年剩餘期間的成本時,兩個季度的情況有點不同。第三季我們其實沒有太多成本順風。你會記得,相較去年同期,那是一個非常艱難的比較基期。去年第三季我們有非常強的成本順風,其中很大一部分是 2025 年第三季一次性的有利因素,來自已提列成本的產量吸收(volume absorption)。

  • Q3 is the flattest cost quarter, whereas we have pretty significant cost favorability in Q4. That really is driven by lower purchase price of raw materials year on year. It is a little bit of a split pattern between the two quarters. It does amplify with the weaker sales in Q3, the headwinds in Q3, and helps amplify the strengths in Q4.

    第三季是成本最平的一季;而第四季我們則有相當顯著的成本有利因素。這主要是由於原物料採購價格年對年下降所驅動。兩個季度之間呈現有點分裂的型態。這也會在第三季銷售較弱時放大第三季的逆風,並在第四季放大其強勢表現。

  • I think, again, everybody should expect Q3 flattest costs, Q4 pretty strong tailwind for costs.

    我認為,再次強調,大家應該預期第三季成本最為持平,第四季成本會有相當強勁的順風。

  • Operator

    Operator

  • Arun Viswanathan, RBC Capital Markets.

    Arun Viswanathan,RBC Capital Markets。

  • Arun Viswanathan - Analyst

    Arun Viswanathan - Analyst

  • Thanks. I guess my question is just, as you look forward, maybe you can just provide an update on where you stand in the restructuring efforts. Obviously, you talked about the new products growth, but maybe on the diamides and Cyazypyr, do you think the pressure has stopped there?

    謝謝。我想我的問題是,展望未來,能否請你們更新一下重組工作的進展。顯然你們談到了新產品的成長,但就二醯胺類(diamides)和 Cyazypyr 而言,你們認為那邊的壓力已經停止了嗎?

  • Are you guys holding gross margin stable? As you look into fiscal 2027, do you expect continued growth on that front? What could you provide as far as where you are on some of these restructuring efforts?

    你們是否能維持毛利率穩定?展望 2027 財年,你們是否預期這方面仍會持續成長?關於這些重組工作,你們目前進度如何,可以提供哪些資訊?

  • Pierre Brondeau - Chairman of the Board, Chief Executive Officer

    Pierre Brondeau - Chairman of the Board, Chief Executive Officer

  • We really have to separate when we talk about diamide, Rynaxypyr and Cyazypyr. Cyazypyr is data-protected. There is no generic in the major countries today. It's a difficult product to make. We are anticipating the 2028, 2029 period when we will lose data protection. To avoid it to be taken by surprise like we did in Rynaxypyr, we're preparing in advance formulation and having a defense strategy. That is a 2028, 2029 problem.

    談到二醯胺類時,我們必須把 Rynaxypyr 和 Cyazypyr 分開來看。Cyazypyr 仍受資料保護。目前在主要國家還沒有學名藥。這是一個很難製造的產品。我們預期在 2028、2029 年期間會失去資料保護。為了避免像 Rynaxypyr 那樣措手不及,我們正提前準備配方並制定防禦策略。那是 2028、2029 年的問題。

  • For Rynaxypyr, we continue the strategy as we have defined so far. So far, it is proving to worthy. I would say the positive or good surprise for me is that we keep on finding ways to lower our manufacturing cost, which is giving us a couple of things. It's protecting our gross margin and it's positioning the product better to gain market share over the lower-end insecticides.

    至於 Rynaxypyr,我們會持續執行目前已定義的策略。到目前為止,這項策略證明是值得的。我會說,對我而言正面或好的驚喜是,我們持續找到降低製造成本的方法,這帶來幾個效果。它在保護我們的毛利率,同時也讓產品在相對低端的殺蟲劑市場中更有利於取得市占。

  • A total focus between the volume and the cost is when we get into 2027 and beyond for Rynaxypyr to protect the earnings contribution of the product to the P&L of the company. I would say that right now all indicators are going that way.

    在 2027 年及之後,針對 Rynaxypyr,我們會在銷量與成本之間保持高度聚焦,以保護該產品對公司損益表(P&L)的獲利貢獻。我會說,目前所有指標都朝這個方向發展。

  • As I said, it will not be viewed as a growth product, but the cost restructuring keeps on going positively. It's going to position us very competitively versus the quality generics, giving us a lot of flexibility to act and giving us a premium on the high-end product, which we are growing very fast. Cyazypyr is a different story. It is still a very profitable product, which is growing in the mid-single digits, and for which we are preparing the 2028 post-data protection situation.

    如我所說,它不會被視為成長型產品,但成本重組仍在持續並呈現正向進展。這將使我們在面對高品質學名藥時具備很強的競爭力,給我們很大的行動彈性,並讓我們在高端產品上維持溢價,而高端產品我們成長非常快。Cyazypyr 則是另一個故事。它仍是一個非常高獲利的產品,成長約為中個位數,且我們正在為 2028 年資料保護到期後的情境做準備。

  • Operator

    Operator

  • Ben Theurer, Barclays.

    Ben Theurer,Barclays。

  • Benjamin Theurer - Analyst

    Benjamin Theurer - Analyst

  • Yeah, good morning. Thanks for taking my question. A lot being touched upon already, I just wanted to maybe go back and understand a little bit what your expectation is in terms of just profit improvement as we move into 2027, 2028, the ramp with the new active ingredient, and still some of the headwinds you've alluded to, Pierre, earlier, as it relates to the diamides, et cetera. How should we think about that?

    是的,早安。謝謝讓我提問。很多內容已經被提到,我只是想回頭再理解一下,當我們走向 2027、2028 年時,就獲利改善的預期而言,你們怎麼看:包括新有效成分的放量爬坡,以及你先前提到、與二醯胺類等相關的一些逆風因素。我們應該如何思考這件事?

  • I remember earlier in the year you've talked about something like mid-teens EBITDA growth into 2027, 2028. Do you think that can still hold based on also the fact that we have a lower starting base, or how should we think about the growth algorithm as we move into 2027, 2028?

    我記得今年稍早你們提到,到了 2027、2028 年 EBITDA 可能有類似中十位數(mid-teens)的成長。考量到我們目前的起始基期較低,你認為這個目標仍能成立嗎?或者我們在邁向 2027、2028 年時,應該如何看待成長算法(growth algorithm)?

  • Pierre Brondeau - Chairman of the Board, Chief Executive Officer

    Pierre Brondeau - Chairman of the Board, Chief Executive Officer

  • I think 2027 diamide. I'm going to talk about Rynaxypyr because, as I said again, Cyazypyr in 2027. We are expecting revenues and earnings growth in 2027. Rynaxypyr, I believe will be at least the earnings contribution of 2026. Number one driver in this one is very important. That's the one I'm the most confident in because it is really happening right now, is the contribution of the high-end diamide mix and product.

    我想談 2027 年的二醯胺類。我會聚焦在 Rynaxypyr,因為如我再次所說,Cyazypyr 在 2027 年(的情況不同)。我們預期 2027 年營收與獲利都會成長。我相信 Rynaxypyr 至少能維持 2026 年的獲利貢獻水準。其中最重要的第一大驅動因素——也是我最有信心的一項,因為它現在就正在發生——是高端二醯胺類產品組合與產品本身的貢獻。

  • Our portfolio mix is changing very much towards those product. We actually have and are expecting very soon a registration which will impact 2027. It's going to impact 2026 in Brazil, which is a blend of Rynaxypyr indoxacarb, which is a very important product to address resistance. That's going to be a source of growth, significant for us next year.

    我們的產品組合正大幅轉向這些產品。我們實際上已經取得、並且預期很快會有一項登記核准(registration),將影響 2027 年。它會在巴西影響 2026 年,這是一個 Rynaxypyr 與茚蟲威(indoxacarb)的混配產品,對於因應抗藥性非常重要。這將成為我們明年顯著的成長來源。

  • What is to be proven, I have to be clear on this one, it's a Q3, Q4 story for us to be checked, is how fast and how much we can penetrate the lower-end market of the Rynaxypyr using a low manufacturing cost with a single. Indications are good, but I don't want to declare victory yet until I've seen it in Q3, Q4 in North America and Brazil.

    需要被驗證的是——我必須把這點說清楚——對我們而言這會是第三季、第四季要檢驗的故事:也就是我們能以多快的速度、以及多大的幅度,利用低製造成本的單劑(single)Rynaxypyr 產品切入較低端市場。目前跡象良好,但在我於北美與巴西看到第三季、第四季的實際表現之前,我還不想宣告勝利。

  • Really, I am not seeing, as you remember at the beginning of the Q&A, I gave a bridge into 2027. I believe that Rynaxypyr will not handicap our performance in 2027.

    事實上,我沒有看到——如你記得在問答一開始我提供了通往 2027 年的橋接——我相信 Rynaxypyr 不會在 2027 年拖累我們的表現。

  • Operator

    Operator

  • This concludes the FMC Corporation earnings call. Thank you for attending. You may now disconnect.

    FMC Corporation 法說會到此結束。感謝各位與會。您現在可以斷線。